5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients (CTCtrap)
Date du début: 1 sept. 2012, Date de fin: 31 août 2016,
"Chemotherapy is slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells and has proven to be more effective with markedly fewer side effects. During the course of the disease alternative oncogenic signaling pathways take over inevitably leading to drug resistance. As a consequence renewed tumor analysis is required to redefine the optimal treat ...
Voir le projet
12
Participants partenaires
TERMINÉ
Studying Resistance to Cancer Therapeutics in Prostate Cancer (RESICT-PC)
Date du début: 1 mai 2014, Date de fin: 30 avr. 2016,
Several new therapies have been recently approved for the treatment of castration-resistant prostate cancer (CRPC) but drug resistance invariably develops and eventually causes death. Currently, the knowledge on the molecular mechanisms underlying resistance is limited; this is an area of urgent unmet medical need to allow improved treatments for patients. This study proposes a multidisciplinary e ...
Voir le projet
1
Participant partenaire
TERMINÉ
CHD1 Deletion: Implications to Outcome and Treatment in Prostate Cancer (CDELP)
Date du début: 4 avr. 2014, Date de fin: 3 avr. 2016,
Prostate cancer can be stratified as ETS gene rearranged (ETSR) andnon-rearranged (ETSNR), with the latter comprising a heterogeneousgroup of 50-60% of all cancers. This project will characterize a subgroupof ETSNR cancers that have a CHD1 deletion (CHD1del). Recentsequencing studies have elucidated CHD1- cancers as ETSNR, andcommonly PTEN and p53 wildtype and SPOP mutated, comprising up to26% of ...
Voir le projet
1
Participant partenaire
TERMINÉ
Systems Biology of Colorectal Cancer (SYSCOL)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,
Colorectal cancer (CRC) is one of the most common cancers in both males and females, and it is perhaps the best understood of all epithelial tumors in terms of its molecular origin. Yet, despite large amount of work that has concentrated on understanding of colon tumorigenesis, we still do not know the full complement of molecular lesions that are individually necessary – and together sufficient – ...
Voir le projet
11
Participants partenaires
TERMINÉ
Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE)
Date du début: 1 juin 2009, Date de fin: 30 nov. 2012,
Recombinant growth hormone (GH) has been used since 1985. Current indications for GH use in children include GH deficiency and an increasing number of conditions where childhood short stature is not primarily due to deficient GH secretion. Approximately 40 000 children in the EU are treated with daily injections of GH. The efficacy of GH to increase adult height is undisputed in children with seve ...
Voir le projet